Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lyxia is a private biotechnology company developing and commercializing microalgae-derived nutritional and personal care ingredients. The company uses a cultivation platform for microalgae and cyanobacteria grown with seawater, sunlight, and carbon dioxide to produce specialty products for food, nutrition, pharmaceutical, cosmetics, and feed markets. Its lead marketed offerings center on vegan omega-3 ingredients under the AlgaLab brand, including EPA-rich extracts and blended EPA/DHA oils. Lyxia also indicates development of protein and functional polysaccharide ingredients derived from algal biomass. The company appears to operate across the United States and China, with commercial-scale production assets in China and corporate roots in Delaware/California.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lyxia.